Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Capital Expenditures (2016 - 2021)

Spero Therapeutics' Capital Expenditures history spans 6 years, with the latest figure at -$39000.0 for Q4 2021.

  • For Q4 2021, Capital Expenditures fell 425.0% year-over-year to -$39000.0; the TTM value through Dec 2021 reached $24000.0, down 84.71%, while the annual FY2021 figure was -$39000.0, 124.84% down from the prior year.
  • Capital Expenditures reached -$39000.0 in Q4 2021 per SPRO's latest filing, down from $12000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q4 2018 to a low of -$39000.0 in Q4 2021.
  • Average Capital Expenditures over 5 years is $258636.4, with a median of $51000.0 recorded in 2020.
  • Peak YoY movement for Capital Expenditures: soared 241500.0% in 2018, then plummeted 425.0% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at -$1000.0 in 2017, then skyrocketed by 241500.0% to $2.4 million in 2018, then plummeted by 94.66% to $129000.0 in 2019, then crashed by 90.7% to $12000.0 in 2020, then tumbled by 425.0% to -$39000.0 in 2021.
  • Per Business Quant, the three most recent readings for SPRO's Capital Expenditures are -$39000.0 (Q4 2021), $12000.0 (Q4 2020), and $51000.0 (Q3 2020).